麻豆国产精品一二三在线观-麻豆国产精品一二三在线观看-麻豆国产精品一区二区-麻豆国产精品永久免费视频-麻豆国产巨作av剧情-麻豆国产蜜桃臀视频在线观看

泰和誠醫療,concord medical,  
泰和誠是一家專業的醫療服務公司，擁有目前中國最大的腫瘤放射治療和影像診斷網絡。自成立以來，泰和誠一直致力于向中國醫療領域引進國際高科技大型醫療診斷治療設備，尤其是世界上技術最前沿的腫瘤診斷與放射治療設備，努力為腫瘤患者提供先進而有效的診療手段和優質的醫療服務。時至今日，泰和誠的腫瘤醫療服務網絡已經覆蓋了中國20多個省市的逾35個主要城市，并繼續在更多的地區積極拓展相關的業務。

通過租賃和提供專業管理的方式，泰和誠在中國許多醫院都建立了腫瘤診療中心。通常每個中心都配備一套先進而昂貴的放射治療和影像診斷設備，如醫用加速器（包括高端的直線加速器和回旋加速器）、頭部伽瑪刀系統、體部伽瑪刀系統、正電子發射計算機斷層影像掃描系統或磁共振成像系統。公司向網絡各中心的醫生提供醫療支持服務，如組織醫生會診和醫學研究等。

為進一步增強公司的業務發展，提高公司的聲譽，泰和誠投資的兩家腫瘤專科醫院（包括長安泰和國際腫瘤中心和北京質子中心）正在建設之中，將集中目前國際上最先進的設備與技術，為腫瘤患者提供更加豐富的診療手段和更加細分化的服務。

據統計，在2008年，癌癥是中國居民死亡的首要病因。而與發達國家相比，中國國內的放射治療和影像診斷設備的普及率卻很低。根據Frost & Sullivan提供的最新數據, 2008年至2015年間，中國放射治療和影像診斷市場的復合年均增長率預計將達22.4%。增長的主要驅動因素包括中國癌癥發病率的不斷增長, 醫生和患者對癌癥的認知度越來越高，以及醫院采用先進的放射治療和影像診斷技術。同時，家庭可支配收入和政府醫療保健支出的不斷增長也將進一步提高人們對癌癥治療和診斷費用的支付能力。

泰和誠分布在全國的龐大網絡、在腫瘤放射治療和影像診斷領域的豐富經驗，以及業內領先的專家團隊使我們能夠不斷滿足中國放射治療和影像診斷服務市場的迫切需要和不斷推動行業的健康發展。

CMS partners with hospitals to build radiotherapy and diagnostic imaging centers. Each center is typically equipped with a primary unit of advanced radiotherapy and diagnostic imaging equipment, such as linear accelerators, head gamma knife systems, body gamma knife systems, positron emission tomography-computed tomography (PET-CT) scanners or magnetic resonance imaging (MRI) scanners. The Company provides clinical support services to doctors working in the centers in its network, such as organizing joint diagnosis among doctors in its network and clinical research, while its hospital partners are responsible for the centers' clinical activities, doctors' medical decisions and the employment of the doctors.

Concord Medical Services Holdings Limited ("CMS" or "the Company") operates China's largest network in terms of revenue and total number of centers in operation in 2008. Since its inception CMS has been committed to building an extensive network of radiotherapy and diagnostic imaging centers in China and employing state-of-the art medical technology to sustain lives and reduce sufferings. Today, the Company operates a network of more than 80 centers spanning more than 35 cities and 20 provinces and administrative regions in China.

To further enhance its reputation and to employ high quality doctors, the Company plans to establish and operate specialty cancer hospitals in China. Its first specialty cancer hospital, the Chang'an CMS International Cancer Center, in Xi'an, Shaanxi Province, is expected to be operational in early 2010. The Company is also in the process of establishing the Beijing Proton Medical Center, which is expected to commence operations in 2012.

Cancer was the leading cause of death in China in 2008, yet there is a relatively low penetration rate of radiotherapy and diagnostic imaging equipment compared to developed countries. According to Frost & Sullivan, the radiotherapy and diagnostic imaging market in China is expected to grow at a CAGR of 22.4% between 2008 and 2015. Growth drivers include increasing cancer rates in China, growing awareness among physicians and patients and hospitals' adoption of advanced radiotherapy and diagnostic imaging technologies. Furthermore, rising household disposable income and government healthcare expenditures will increase the affordability of such cancer treatment and diagnosis technologies.

With its leading network and its experience and expertise, the Company is uniquely positioned to address the underserved radiotherapy and diagnostic imaging services market in China.